Idera Pharmaceuticals, Inc.

368 articles with Idera Pharmaceuticals, Inc.

• Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

  1/17/2023

  Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. (“Aceragen,” the “Company,” “we,” “us,” or “our”) and “ACGN”.

• Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/14/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022.

• 

  Idera Bolsters Rare Disease Portfolio with Aceragen Buyout

  9/29/2022

  Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024.

• Idera Pharmaceuticals Acquires Aceragen

  9/28/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments.

• Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

  8/9/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2022.

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

• Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC– Enrollment Stopped Early for Efficacy –

  5/17/2022

  Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Idera’s synthetic Toll-like receptor 9 agonist.

• 

  Idera Halts Enrollment For Melanoma Trial Following Positive Early Data

  5/17/2022

  Idera Pharmaceuticals has stopped patient enrollment early for its Phase II trial on a candidate melanoma drug after interim data delivered impressive results.

• Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/5/2022

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2022.

• Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

  3/31/2022

  Idera Pharmaceuticals, Inc. reported its financial and operational results for the fourth quarter and year ended December 31, 2021.

• Idera Pharmaceuticals Announces Tilsotolimod Updates

  12/14/2021

  Idera Pharmaceuticals, Inc. announced clinical updates regarding tilsotolimod, its synthetic Toll-like receptor 9 agonist.

• Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/8/2021

  Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2021.

• Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/9/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021.

• Idera Pharmaceuticals Announces Corporate Updates

  5/18/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint.

• Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

  4/29/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021.

• 

  Idera’s Melanoma Candidate Hits Snag in Phase III Trial

  3/19/2021

  A Phase III trial from Idera Pharmaceuticals did not reach the primary endpoint of ORR in patients with anti-PD-1 refractory advanced melanoma treated with a combination regimen comprising ipilimumab and the company’s investigational agent tilsotolimod.

• Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma– Objective Response Rate Endpoint Not Met –

  3/18/2021

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR)

• Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate UpdateILLUMINATE-301 Continues on Track for Data Later this Month

  3/1/2021

  Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.

• Idera Pharmaceuticals to Present at Upcoming Conferences - Jan 11, 2021

  1/11/2021

  Idera Pharmaceuticals, Inc. announced that it will provide a company outlook for 2021 at upcoming conferences.

• Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

  12/15/2020

  Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purchase Agreement”), resulting in aggregate proceeds of up to $20.7 million in common stock and warrant investment by funds affiliated with an institutional investor.